Navigation Links
Surveyed Neurologists Report Significantly Higher Relapsing-Remitting Multiple Sclerosis Patient Shares for Gilenya and Tysabri, Compared With One Year Ago

EXTON, Pa., Dec. 12, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that physician-reported patient shares for Novartis's Gilenya and Biogen Idec's Tysabri are 8 percent and 10 percent among relapsing-remitting multiple sclerosis (RR-MS) patients treated with a disease-modifying therapy (DMT) across the EU5 (France, Germany, Italy, Spain and the United Kingdom)—significantly higher than those reported by EU5 neurologists surveyed in 2012. Surveyed neurologists also report that recent changes in treatment management include a shift toward earlier and more-aggressive treatment and increased use of the anti-JCV antibody assay, changes that are consistent with the increased patient shares reported for Gilenya and Tysabri. Survey data indicate that these agents occupy distinct niches, with Gilenya a preferred second-line therapy in JCV-positive patients and Tysabri a preferred second-line therapy in JCV-negative patients.


The TreatmentTrends: Multiple Sclerosis (EU) 2013 report finds that, despite fewer than 30 percent of surveyed neurologists reporting access to Genzyme's* Aubagio and Genzyme/Bayer HealthCare's Lemtrada—and given the limited time these agents had been available at the time the survey was fielded—these DMTs have nevertheless captured a 1 percent physician-reported weighted MS patient share. The data also reveal that surveyed neurologists anticipate substantial changes in DMT use in the coming months as access to Aubagio and Lemtrada expands and as new products, notably Biogen Idec's Tecfidera, become available. Neurologists indicate that Aubagio will most likely compete with first-line products (i.e., Biogen Idec's Avonex, Bayer HealthCare's Betaferon and Teva's Copaxone), while Tecfidera may replace these products as well as Merck Serono's Rebif and Gilenya. Lemtrada, conversely, will most likely compete with Tysabri or would not replace an existing DMT, suggesting anticipated use as a last-line therapy.

"The European MS market is entering a dynamic period with two recent DMT launches and as many as six new DMTs launching in the next five years," said Decision Resources Group Senior Business Insights Analyst Georgiana L. Kuhlmann, S.M. "Our data find that gains for new brands will likely come at the expense of the interferon-beta therapies and Copaxone."

*Genzyme is a wholly-owned subsidiary of Sanofi.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort


SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. At Twelve Months Post-Launch, the Majority of Surveyed Oncologists Have Prescribed Xtandi to Their Docetaxel-Pretreated Metastatic Castrate-Resistant Prostate Cancer Patients
2. Surveyed Oncologists Indicate that the Use of Biomarker Testing is Increasing Rapidly in Non-Small-Cell Lung Cancer in China and South Korea
3. According to Surveyed EU5 Oncologists, Zelboraf Captures 50 Percent Patient Share of the First-Line BRAF-Mutation Positive Malignant Melanoma Population
4. According to Surveyed U.S. Oncologists, Zelboraf is the Patient Share Leader in First-Line BRAF-Mutation Positive Malignant Melanoma
5. Surveyed Endocrinologists Consider Eli Lillys Dulaglutide To Have an Edge Over Competitors for the Treatment of Type 2 Diabetes Patients Who Are Inadequately Controlled On Metformin
6. Two-Thirds of Surveyed U.S. Neurologists Have Prescribed Genzymes Aubagio to Their Multiple Sclerosis Patients at One Year Post-Launch
7. Surveyed EU5 Rheumatologists Prescribe Biologics to Approximately Half of Their DMARD-Treated Psoriatic Arthritis Patients
8. Surveyed EU5 Oncologists Plan Increased Uptake of Perjeta for HER2-Positive Breast Cancer, But Expect Reimbursement Hurdles for Perjeta Plus Kadcycla
9. Surveyed Physicians Report that Invokana Captures a Small Percentage of Patient Share in the Type 2 Diabetes Drug Market, With Significant Increases Expected Six Months from Now
10. Surveyed U.S. Rheumatologists are Moderately Satisfied with Biologic Agents and Xeljanz to Treat Rheumatoid Arthritis
11. More than a Third of Chronic Kidney Disease-Non-Dialysis Patients are Likely Candidates for FG-4592/ASP1517, According to Surveyed EU5 Nephrologists
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... addition of the "2016 Future Horizons ... of Abuse Testing Market: Supplier Shares, Country ... report to their offering. --> ... the "2016 Future Horizons and Growth ...
(Date:11/26/2015)... ) has ... Future Horizons and Growth Strategies in the ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> ) has announced the ... and Growth Strategies in the German Drugs ...
(Date:11/26/2015)... -- Research and Markets ( ) has announced ... by Type (Dressings, Therapy Devices, Active Wound Care), Application ... and Geography - Global Forecast to 2020" report ... --> The purpose of this report is ... global advanced wound care market. It involves deep dive ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... The McHenry County law ... successful appellate decision obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys ... Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to court documents, Adcock ...
(Date:11/25/2015)... ... November 25, 2015 , ... SCOTTSDALE, AZ) - Today, ... in both surgical and non-surgical treatments, announced the expansion of his private practice ... Surgery. , Highly trained and nationally recognized for his natural approach, Dr. ...
(Date:11/25/2015)... MI (PRWEB) , ... November 25, 2015 , ... In ... Presence Resurrection Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy ... medical and surgical intensive care units (totaling 30 beds) from May 2014 through October ...
(Date:11/25/2015)... Missouri (PRWEB) , ... November 25, 2015 , ... ... HEAL, will provide scholarships for people struggling with eating disorders as a result ... from the second annual event, held at Fox Run Golf Club in Eureka, ...
(Date:11/25/2015)... ... 2015 , ... Privately owned Contract Development and Manufacturing Organization ... current state of the art research, development and manufacturing facility outside of Fort ... capacity as well as to support its clients’ growing research and development and ...
Breaking Medicine News(10 mins):